Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 18.5%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 234,800 shares, a decline of 18.5% from the October 15th total of 288,200 shares. Based on an average trading volume of 301,600 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Allarity Therapeutics

A hedge fund recently bought a new stake in Allarity Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 261,000 shares of the company’s stock, valued at approximately $195,000. Armistice Capital LLC owned approximately 9.56% of Allarity Therapeutics at the end of the most recent reporting period. 10.70% of the stock is owned by institutional investors.

Allarity Therapeutics Stock Performance

Shares of ALLR stock opened at $0.48 on Wednesday. The company’s fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $4.73. Allarity Therapeutics has a 52 week low of $0.45 and a 52 week high of $1,890.00.

Allarity Therapeutics (NASDAQ:ALLR) last issued its earnings results on Monday, August 14th. The company reported ($26.28) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Allarity Therapeutics will post -197.6 EPS for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.